Distinguished in Mast Cell Activation Syndrome (MCAS)

Dr. Srdan Verstovsek

Houston, TX
Distinguished
in Mast Cell Activation Syndrome (MCAS)
Specialties:Oncology | Hematology Oncology
Age:59
29 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Srdan Verstovsek is an Oncologist and a Hematologist Oncology provider in Houston, Texas. Dr. Verstovsek has been practicing medicine for over 29 years and is rated as a Distinguished provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 490 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 22 articles and participated in 1 clinical trial in the study of Mast Cell Activation Syndrome (MCAS).

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

1515 Holcombe Blvd, Houston, TX 77030
713-792-6161

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: IFN-alpha2a
Study Phase: Phase 2
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Phase: Phase 2
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: August 26, 2024
Intervention Type: Other, Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: GB2064
Study Phase: Phase 2
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 2
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Enrollment Status: Terminated
Publish Date: May 15, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

490 Total Publications

Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.
Journal: Future oncology (London, England)
Published: July 29, 2024
Similar Doctors
Expertise in
34
conditions
Dr. Prithviraj H. Bose
Hematology Oncology | Hematology | Oncology
Expertise in
34
conditions
Dr. Prithviraj H. Bose
Hematology Oncology | Hematology | Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
713-792-6127
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Bose and is rated as an Elite provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
37
conditions
Dr. Naveen Pemmaraju
Oncology | Hematology
Expertise in
37
conditions
Dr. Naveen Pemmaraju
Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (0.6 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naveen Pemmaraju is an Oncologist and a Hematologist in Houston, Texas. Dr. Pemmaraju and is rated as an Elite provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. Preetesh M. Jain
Oncology
Expertise in
22
conditions
Dr. Preetesh M. Jain
Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
713-792-6127
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Preetesh Jain is an Oncologist in Houston, Texas. Dr. Jain and is rated as an Elite provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile